A large proportion of patients who have erectile dysfunction also have coronary artery disease(CAD). In these patients, nitrate therapy is a contraindication to the use of sildenafil. To assess whether the metabolic a...A large proportion of patients who have erectile dysfunction also have coronary artery disease(CAD). In these patients, nitrate therapy is a contraindication to the use of sildenafil. To assess whether the metabolic anti-ischemic agent, trimetazidine, is effective in controlling episodes ofmyocardial ischemia during sexual activity in patients who have CAD and use longterm nitrate therapy, we studied 38 men(57±6 years of age) who had proved CAD. Patients underwent 24-hour ambulatory electrocardiographic monitoring at baseline, after 1 week of oral nitrate therapy(20 mg 3 times a day), and after 1 week of trimetazidine(20 mg 3 times a day). Patients were asked to engage in< 1 session of sexual intercourse during each session of ambulatory electrocardiographic monitoring. They were instructed to take sildenafil(100 mg) 1 hour before sexual intercourse performed at baseline and during therapy with trimetazidine and sildenafil or placebo(blinded) during therapy with nitrates. A decrease in total ischemic burden was observed with nitrates and trimetazidine compared with baseline(-3±1.2 episodes/patient/24 hours vs-5±1.3 episodes/patient/24 hours and-6±5 min/patient/24 hours vs-8±3 min/patient/ 24 hours, p< 0.01 for nitrates and trimetazidine vs baseline). Trimetazidine plus sildenafil was more effective in controlling episodes of myocardial ischemia during sexual activity than nitrates alone(-45±11%vs-18±7%, p< 0.04). In conclusion, in patients who have CAD, combination therapy with sildenafil and trimetazidine is more effective than nitrate therapy in the control of ischemic episodes during sexual activity, suggesting that long-term nitrate therapy may be safely switched to trimetazidine therapy when therapy for erectile dysfunction is required.展开更多
文摘A large proportion of patients who have erectile dysfunction also have coronary artery disease(CAD). In these patients, nitrate therapy is a contraindication to the use of sildenafil. To assess whether the metabolic anti-ischemic agent, trimetazidine, is effective in controlling episodes ofmyocardial ischemia during sexual activity in patients who have CAD and use longterm nitrate therapy, we studied 38 men(57±6 years of age) who had proved CAD. Patients underwent 24-hour ambulatory electrocardiographic monitoring at baseline, after 1 week of oral nitrate therapy(20 mg 3 times a day), and after 1 week of trimetazidine(20 mg 3 times a day). Patients were asked to engage in< 1 session of sexual intercourse during each session of ambulatory electrocardiographic monitoring. They were instructed to take sildenafil(100 mg) 1 hour before sexual intercourse performed at baseline and during therapy with trimetazidine and sildenafil or placebo(blinded) during therapy with nitrates. A decrease in total ischemic burden was observed with nitrates and trimetazidine compared with baseline(-3±1.2 episodes/patient/24 hours vs-5±1.3 episodes/patient/24 hours and-6±5 min/patient/24 hours vs-8±3 min/patient/ 24 hours, p< 0.01 for nitrates and trimetazidine vs baseline). Trimetazidine plus sildenafil was more effective in controlling episodes of myocardial ischemia during sexual activity than nitrates alone(-45±11%vs-18±7%, p< 0.04). In conclusion, in patients who have CAD, combination therapy with sildenafil and trimetazidine is more effective than nitrate therapy in the control of ischemic episodes during sexual activity, suggesting that long-term nitrate therapy may be safely switched to trimetazidine therapy when therapy for erectile dysfunction is required.
